Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females.
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females. This study will utilize a randomized, double-blind, placebo group study design. Prior to any data collection, potential participants will be explained the protocol and then review and sign an IRB-approved consent form. Healthy male and female (n=40) participants who report regularly practicing or competing in high-intensity multi-modal resistance based exercise will complete the study protocol.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Rice Flour. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. |
|
| Tart Cherry Extract Powder | Experimental | Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tart Cherry Extract Powder | Dietary Supplement | Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Counter movement Jump Height | Jump height from counter movement jump | 10 days |
| Counter movement jump peak propulsive force (N) | Peak propulsive force (N) from counter movement jump | 10 days |
| Counter movement jump relative breaking force (N) | relative breaking force (N/kg) from counter movement jump | 10 days |
| Isokinetic knee extension maximal voluntary contraction. | Peak isokinetic knee extension force (N) from a isokinetic knee extension exercise using a Biodex System 3 | 10 days |
| Isometric mid-thigh pull maximal voluntary contraction | Isometric maximal voluntary contraction peak force will be measured using an isometric mid-thigh pull assessment. Peak force production will be measured in Newtons. | 10 days |
| Perceived recovery Visual Analog Scale | Perceived recovery Visual Analog Scale ranging from 0 (worst) to 100 (best) | 10 days |
| Perceived soreness Visual Analog Scale | Perceived soreness Visual Analog Scale ranging from 0 (worst) to 100 (best) | 10 days |
| Pain to Pressure threshold |
| Measure | Description | Time Frame |
|---|---|---|
| Peak power | Peak power during a wingate anaerobic test | 10 days |
| Changes in Protein carbonyls concentration | Protein carbonyls concentration changes |
| Measure | Description | Time Frame |
|---|---|---|
| Resting Heart Rate | Resting heart rate at all study visits | 10 days |
| Resting Blood pressure | Resting Blood pressure at all study visits | 10 days |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chad M Kerksick, PhD | Lindenwood University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Exercise and Performance Nutrition Laboratory | Saint Charles | Missouri | 63301 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| D063806 | Myalgia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
This study will utilize a randomized, double-blind, placebo group study design
Not provided
Not provided
In a double-blind, placebo-controlled fashion, participants will be randomly assigned to one of two supplementation groups. One group will be assigned to ingest rice flour which will serve as a placebo group. The other group will be assigned to ingest 500 mg/day of Tart Cherry Extract Powder (ADSO Naturals). All study materials will be prepared into gelatin capsules of identical size, color, shape, and transparency.
| Placebo | Dietary Supplement | Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days. |
|
Pain to Pressure threshold from algometry (higher = less sore). Minimum values are 0 N, maximum values are 110 N
| 10 days |
| Changes in Creatine Kinase concentrations | Changes in Creatine kinase concentrations following damaging exercise | 10 days |
| Changes in Creatine Kinase-myocardial band concentrations | Changes in Creatine kinase-myocardial band concentrations following damaging exercise | 10 days |
| Sprint time | Fastest and average sprint time during 15 30-meter sprint recorded using digitally timed timing gates | Baseline |
| 10 days |
| Changes in 8-isoprostane concentration | 8-isoprostane concentration changes | 10 days |
| Changes in testosterone-cortisol ratio | Testosterone-cortisol ratio changes | 10 days |
| Changes in TNF-alpha concentration | Changes in TNF-alpha concentration | 10 days |
| Changes in IL-6 concentration | Changes in IL-6 concentration | 10 days |
| Changes in IL-10 concentration | Changes in IL-10 concentration | 10 days |
| Desire to exercise visual analog scale | Desire to exercise visual analog scale (0 = not ready to train, 100 = very ready to train) | 10 days |
| Pittsburgh sleepiness Scale Score | Pittsburgh sleepiness Scale Score (lower scores indicate higher level of sleepiness) | 10 days |
| Changes in Uric Acid Concentrations | Changes in Uric Acid concentrations | 10 days |
| Reported Adverse Events | Self-Reported Adverse Events | 10 days |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D059352 | Musculoskeletal Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |